Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Strategy” second quarter 2025 ...

Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its phase 3 trial.

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an eight-week period.

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

Key Takeaways A new Amgen weight reduction drug, MariTide, has bred successful results after a 52-week study. Still, AMGN stock declined almost 5% on Tuesday as weight loss reduction was at the ...

The injection, MariTide, helped patients with obesity lose up to 20% of their weight on average after a year, with no plateau. Ahead of the data, several analysts said they wanted MariTide to show ...

NodThera, a privately-held biotech working in chronic inflammatory diseases through selective modulation of the NLRP3 ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. Explore more details here.

THOUSAND OAKS, Calif., Nov. 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart ...

If MariTide's upcoming phase 3 trial fails to excite investors, they'll still get to hang on to the dividends they receive. Amgen offers a 3.3% yield at recent prices, and the company is known for ...